Conference abstract · 2018
Conference abstractPublished 1 Dec 2016
The story of glatiramer acetate (Copaxone) in the treatment of multiple sclerosis - The potential for neuroprotection by immunomodulat
The Weizmann Institute of Science, Israel
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Multiple sclerosis (MS) is currently recognized as complex diseases in which inflammatory autoimmune reactivity in the central nervous system (CNS) results in demyelination, axonal and neuronal pathology. Treatment strategies thus aim to reduce the detrimental inflammation and induce neuroprotective repair processes. The synthetic copolymer Copaxone (Glatiramer acetate, GA), an approved drug for the treatment of MS, is the first and so far the only therapeutic agent to have a copolymer as its active ingredient. Using the animal model of MS, experimental autoimmune encephalomyelitis (EAE), the mechanism of action of GA was elucidated. These studies indicated that GA treatment generates immunomodulatory shift from the inflammatory towards the anti-inflammatory pathways, such as Th2-cells that cross the blood brain barrier (BBB) and secrete in situ anti-inflammatory cytokines as well as T-regulatory cells (Tregs) that suppress the disease. The consequences of GA treatment on the CNS injury inflicted by the disease were studied using immunohistochemistry, electron microscopy and magnetic resonance imaging. These analyses revealed reduced demyelination and neuro-axonal damages as well as neuroprotective repair processes such as neurotrophic factors secretion, remyelination and neurogenesis. These combined findings indicate that immunomodulatory treatment can counteract the neurodegenerative disease course, supporting linkage between immunomodulation, neuroprotection and therapeutic activity in the CNS.
Ask about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 1 Dec 2016
The story of Glatiramer acetate (Copaxone) in the treatment of multiple sclerosis: The potential for neuroprotection by immunomodulatory treatment
Conference abstract · 13 Oct 2016
The story of Copaxone (glatiramer acetate) in the treatment of multiple sclerosis and its new applications
Conference abstract · 2018
FROM BASIC RESEARCH TO DRUG DEVELOPMENT: THE STORY OF COPAXONE (GLATIRAMER ACETATE) IN THE TREATMENT OF MULTIPLE SCLEROSIS AND POTENTIAL APPLICATIONS FOR ADDITIONAL PATHOLOGIES
Conference abstract
From basic research to drug development: The story of Copaxone (glatiramer acetate) in the treatment of multiple sclerosis and its new Applications
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- SubjectNeuroscience & Neurology
- SubjectImmunology & Microbiology
- BylineArticles whose byline prints “Rina Aharoni”
